A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients. Materials and methods: This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled. Results: A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2-positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m2 on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m2 every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction. Conclusion: This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.
Abstract
Purpose: We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients. Materials and methods: This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled. Results: A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2-positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m2 on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m2 every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction. Conclusion: This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.
참고문헌 (23)
- McGrogan BT, "Taxanes, microtubules and chemoresistant breast cancer", Biochim Biophys Acta, 1785, pp.96~132 (2008)
- ten Tije AJ, "Pharmacological effects of formulation vehicles : implications for cancer chemotherapy", Clin Pharmacokinet, 42, pp.665~685 (2003)
- Gradishar WJ, "Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer", J Clin Oncol, 27, pp.3611~3619 (2009)
- Gradishar WJ, "Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer", J Clin Oncol, 23, pp.7794~7803 (2005)
- Schmid P, "Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer", N Engl J Med, 379, pp.2108~2121 (2018)
- Ricciuti B, "Immune checkpoint inhibitor outcomes for patients with non-small-cell lng cancer receiving baseline corticosteroids for palliative versus nonpalliative indications", J Clin Oncol, 37, pp.1927~1934 (2019)
- Scott SC, "Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab", J Thorac Oncol, 13, pp.1771~1775 (2018)
- Ibrahim NK, "Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer", J Clin Oncol, 23, pp.6019~6026 (2005)
- Hammond ME, "American Society of Clinical Oncology", College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, 2010, pp.28, 2784~2795
- WolffAC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
- Goldhirsch A, "Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
- Desai N, "Albumin in medicine: pathological and clinical applications", pp.101~119 (2016), Springer
- Fang J, "Factors and mechanism of"EPR"effect and the enhanced antitumor effects of macromolecular drugs including SMANCS", Adv Exp Med Biol, 519, pp.29~49 (2003)
- Yamamoto Y, "Nab-paclitaxel for the treatment of breast cancer : efficacy, safety, and approval", Onco Targets Ther, 4, pp.123~136 (2011)
- Martin M, "nab-Paclitaxel dose and schedule in breast cancer", Breast Cancer Res, 17, pp.81~ (2015)
- "Breast cancer (version 6.2020)" (2020)[URL]
- Blum JL, "Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes", Clin Breast Cancer, 7, pp.850~856 (2007)
- Miles D, "Primary results from IMpassion131, a double-blind placebo-controlled randomized phase III trial of first-line paclitaxel (PAC)±atezolizumab (atezo) for unresectable locally advanced", metastatic triple-negative breast cancer (mTNBC), 2020, pp.31(Suppl 4), S1142~S1215
- Soliman HH, "nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors", Onco Targets Ther, 10, pp.101~112 (2017)
- Seidman AD, "Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors : final results of Cancer and Leukemia Group B protocol 9840", J Clin Oncol, 26, pp.1642~1649 (2008)
- Sparano JA, "Weekly paclitaxel in the adjuvant treatment of breast cancer", N Engl J Med, 358, pp.1663~1671 (2008)
- Marschner N, "Final effectiveness and safety results of NABUCCO : real-world data from a noninterventional, prospective, multicenter study in 697 patients with metastatic breast cancer treated with nab-paclitaxel", Clin Breast Cancer, 18, pp.e1323~e1337 (2018)
- Jackisch C, "Weekly nab-paclitaxel in metastatic breast cancer : summary and results of an expert panel discussion", Breast Care(Basel), 7, pp.137~143 (2012)